This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chowdhury, S. R., Das, D. C., Sunna, T. C., Beyene, J. & Hossain, A. eClinicalMedicine 57, 101860 (2023).
Mujica-Mota, R. E. et al. Qual. Life Res. 24, 909–918 (2015).
Skou, S. T. et al. Nat. Rev. Dis. Primers 8, 48 (2022).
Salisbury, C. et al. Br. J. Gen. Pract. 63, e751–e759 (2013).
Salisbury, C., Johnson, L., Purdy, S., Valderas, J. M. & Montgomery, A. A. Br. J. Gen. Pract. 61, e12–e21 (2011).
Rodrigues, L. P. et al. Age Ageing 51, afac155 (2022).
Bissenbakker, K., Møller, A., Brodersen, J. B. & Jønsson, A. B. R. J. Patient Rep. Outcomes 6, 83 (2022).
Aiyegbusi, O. L. et al. Nat. Med. 30, 650–659 (2024).
Bennett, H. Q. et al. eClinicalMedicine 39, 101041 (2021).
von dem Knesebeck, O. et al. Int. J. Equity Health 14, 17 (2015).
Calvert, M. J. et al. Nat. Med. 28, 1120–1124 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.E.H. receives funding from the National Institute of Health and Care Research (NIHR), NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Centre (ARC) West Midlands, UKRI and UK SPINE. She declares personal fees from Cochlear, Pfizer, Rinri Therapeutics, Astra Zeneca, Aparito and CIS Oncology outside of the submitted work. M.J.C. is director of the Birmingham Health Partners Centre for Regulatory Science and Innovation, director of the Centre for the Centre for Patient Reported Outcomes Research and is an NIHR senior investigator. M.J.C. receives funding from the NIHR, UK Research and Innovation (UKRI), NIHR BRC, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR ARC West Midlands, UK SPINE, European Regional Development Fund – Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. M.C. has received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside of the submitted work. In addition, a family member owns shares in GSK. N.A. receives funding from NIHR ARC West Midlands. C.M. receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), UKRI, NIHR, NIHR BTRU in Precision Transplant and Cellular Therapeutics, and declares personal fees from Aparito outside of the submitted work. No other disclosures were reported.
Rights and permissions
About this article
Cite this article
Hughes, S.E., Anderson, N.E., Hathaway, E. et al. Opportunities and challenges for patient-reported outcome assessment in multimorbidity research and practice. Nat Med (2024). https://doi.org/10.1038/s41591-024-03237-7
Published:
DOI: https://doi.org/10.1038/s41591-024-03237-7